Effect of adenosine kinase, adenosine deaminase and transport inhibitors on striatal dopamine and stereotypy after methamphetamine administration

Neuropharmacology

Volumn 39, Issue 11, 2000, Pages 2124-2132

  Golembiowska, Krystyna ^a   Zylewska, Alicja ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Adenosine; Dopamine release; Methamphetamine; Stereotypy; Striatum

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 IODOTUBERCIDIN; 5' AMINO 5' DEOXYADENOSINE; 6 N CYCLOPENTYLADENOSINE; 9 (2 HYDROXY 3 NONYL)ADENINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE DEAMINASE; ADENOSINE DEAMINASE INHIBITOR; ADENOSINE KINASE; ADENOSINE KINASE INHIBITOR; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; CAFFEINE; DILAZEP; DOPAMINE; ENZYME INHIBITOR; HOMOVANILLIC ACID; METHAMPHETAMINE; PENTOSTATIN;

ADOLESCENT; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN PROTECTION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG EFFECT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOTYPY;

ADENOSINE DEAMINASE; ADENOSINE KINASE; ANIMALS; CORPUS STRIATUM; DILAZEP; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; ENZYME INHIBITORS; MALE; METHAMPHETAMINE; PENTOSTATIN; RATS; RATS, WISTAR; RECEPTORS, PURINERGIC P1; TUBERCIDIN;

EID: 0033849023     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(00)00024-1     Document Type: Article

References (53)

1. Agarwal R.P. Inhibitors of adenosine deaminase. Pharmacology and Therapeutics. 17:1982;399-429.
2. Alexander S.P., Reddington M. The cellular localization of adenosine receptors in rat neostriatum. Neuroscience. 28:1989;561-645.
3. Ballarin M., Fredholm B.B., Ambrosio S., Mahy N. Extracellular levels of adenosine and its metabolites in the striatum of awake rats: inhibition of uptake and metabolism. Acta Physiologica Scandinavica. 142:1991;97-103.
4. 1 receptor agonist, on spontaneous and evoked dopamine release in rat neostriatum. Neuroscience Letters. 185:1995;29-32.
5. Barraco R.A., Coffin V.L., Altman H.J., Phillis J.W. Central effects of adenosine analogs on locomotor activity in mice and antagonism of caffeine. Brain Research. 272:1983;392-395.
6. Cadet J.L., Brannock C. Free radicals and the pathobiology of brain dopamine systems. Neurochemistry International. 32:1998;117-131.
7. Ciruela F., Saura C., Canela E., Mallol J., Lluis C., Franco R. Adenosine-deaminase affects ligand-induced signalling by interacting with cell surface adenosine receptors. FEBS Letters. 380:1996;219-223.
8. Davies L.P., Cook A.F. Inhibition of adenosine kinase and adenosine uptake in guinea-pig CNS tissue by halogenated tubercidin analogues. Life Sciences. 56:1995;345-349.
9. 2 receptors but have potent pharmacological activity in vivo. Biochemical Pharmacology. 35:1986;3021-3029.
10. Delaney S.M., Geiger J.D. Levels of endogenous adenosine in rat striatum. I. Regulation by ionotropic glutamate receptors, nitric oxide and free radicals. Journal of Pharmacology and Experimental Therapeutics. 285:1998;561-567.
11. Delaney S.M., Geiger J.D. Levels of endogenous adenosine in rat striatum. II. Regulation of basal and N-methyl-D-aspartate-induced levels by inhibitors of adenosine transport and metabolism. Journal of Pharmacology and Experimental Therapeutics. 285:1998;568-572.
12. Delle Donne K.T., Sonsalla P.K. Protection against methamphetamine-induced neurotoxicity to neostriatal dopaminergic neurons by adenosine receptor activation. Journal of Pharmacology and Experimental Therapeutics. 27:1994;1320-1326.
13. Dixon A.K., Gubitz A.K., Sirinathsinghji D.J.S., Richardson P.J., Freeman T.C. Tissue distribution of adenosine receptor mRNAs in the rat. British Journal of Pharmacology. 118:1996;1461-1468.
14. Dux E., Fastbom J., Ungerstedt U., Rudolphi K., Fredholm B.B. Protective effect of adenosine and a novel xanthine derivative propentofylline on the cell damage after bilateral carotid occlusion in the gerbil hippocampus. Brain Research. 516:1990;248-256.
15. 2 dopamine receptors in rat striatum. Molecular Brain Research. 14:1992;186-195.
16. Ferré S., Fuxe K., von Euler G., Johansson B., Fredholm B.B. Adenosine-dopamine interactions in the rat brain. Neuroscience. 51:1992;501-512.
17. Ferré S., O'Connor W.T., Fuxe K., Ungerstedt U. The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. Neuroscience. 13:1993;5402-5406.
18. Ferré S., Fredholm B.B., Morelli M., Popoli P., Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends in Neurosciences. 20:1997;482-487.
19. Fleckenstein A.E., Metzger R.R., Wilkins D.G., Gibb J.W., Hanson G.R. Rapid and reversible effects of methamphetamine on dopamine transporters. Journal of Pharmacology and Experimental Therapeutics. 282:1997;834-838.
20. Fredholm B.B., Dunwiddie T.V. How does adenosine inhibit transmitter release? Trends in Pharmacological Sciences. 9:1988;130-134.
21. Fredholm B.B., Abbracchio M.P., Burnstock G., Daly J.W., Harden T.K., Jacobson K.A.et al. VI. Nomenclature and classification of purinoceptors. Pharmacological Reviews. 46:1994;143-156.
22. Geiger J.D., Fyda D.M. Adenosine in the nervous system tissues. Stone T.W. Adenosine in the Nervous System. 1991;1-23 Academic Press, London.
23. Geiger J.D., Lewis J.L., MacIntyre C.J., Nagy J.I. Pharmacokinetics of 2′-deoxycoformycin, an inhibitor of adenosine deaminase, in the rat. Neuropharmacology. 26:1987;1383-1387.
24. Gibb J.W., Kogan F.J. Influence of dopamine synthesis on methamphetamine-induced changes in striatal and adrenal tyrosine hydroxylase. Naunyn-Schmiedeberg's Archives of Pharmacology. 310:1979;185-187.
25. Golembiowska K., Zylewska A. Adenosine receptors - the role on modulation of dopamine and glutamate release in the rat striatum. Polish Journal of Pharmacology. 49:1997;317-322.
26. 2A adenosine receptors attenuate methamphetamine-induced overflow of dopamine in rat striatum. Brain Research. 806:1998;202-209.
27. Golembiowska K., White T.D., Sawynok J. Modulation of adenosine release from rat spinal cord by adenosine deaminase and adenosine kinase inhibitors. Brain Research. 699:1995;315-320.
28. Golembiowska K., White T.D., Sawynok J. Adenosine kinase inhibitors augment release of adenosine from spinal cord slices. European Journal of Pharmacology. 307:1996;157-162.
29. Heffner T.G., Wiley J.N., Williams A.E., Bruns R.F., Conghenour L.L. Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice. Psychopharmacology. 98:1989;31-37.
30. Imperato A., Di Chiara G. Trans-striatal dialysis coupled to reverse phase high performance liquid chromatography with electrochemical detection: a new method for the study of the in vivo release of endogenous dopamine and metabolites. Journal of Neuroscience. 4:1984;966-977.
31. 2A receptor activation on electrically evoked dopamine and acetylcholine release from rat striatal slices. Journal of Pharmacology and Experimental Therapeutics. 267:1993;801-808.
32. Kobayashi T., Yamada T., Okada Y. The levels of adenosine and its metabolites in the guinea pig and rat brain during complete ischemia - in vivo study. Brain Research. 87:1998;211-219.
33. 1 agonist. Journal of Neurochemistry. 60:1993;768-771.
34. Lin Y., Phillis J.W. Deoxycoformycin and oxypurinol: protection against focal ischemic brain injury in the rat. Brain Research. 571:1992;272-280.
35. 14C] adenine in the rhesus monkey. Drug Metabolism and Disposition. 8:1980;5-7.
36. Meghji P. Adenosine production and metabolism. Stone T. Adenosine in the Nervous System. 1991;25-42 Academic Press, London.
37. 2 receptors stimulate c-fos expression in striatal neurons of 6-hydroxydopamine-lesioned rats. Neuroscience. 67:1995;49-55.
38. Murray T.F., Zhang G., Franklin P.H. Manipulation of endogenous adenosine affects seizure susceptibility. Drug Development Research. 28:1993;410-415.
39. Myers S., Pugsley T.A. Decrease in rat striatal dopamine synthesis and metabolism in vivo by metabolically stable adenosine receptor agonists. Brain Research. 375:1986;193-197.
40. Nehlig A., Davel J.-L., Debry G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Research Reviews. 17:1992;139-170.
41. 2 receptors modulate extracellular dopamine levels in rat striatum. Neuroscience Letters. 212:1996;53-56.
42. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1998;Academic Press, San Diego.
43. + depolarization, tetrodotoxin, and NMDA receptor inhibition on extracellular adenosine levels in rat striatum. European Journal of Pharmacology. 234:1993;61-65.
44. Phillis J.W., Smith-Barbour M. The adenosine kinase inhibitor, 5′-iodotubercidin, is not protective against cerebral ischemic injury in the gerbil. Life Sciences. 53:1993;497-502.
45. 2 receptors induces rotational behaviour in response to dopaminergic stimulation in intact rats. European Journal of Pharmacology. 257:1994;21-25.
46. Ricaurte G.A., Guillery R.W., Seiden L.S., Schuster C.R., Moore R.Y. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Research. 235:1982;93-103.
47. 2A receptor agonists on dopamine receptor agonist-induced behavioural responses in rats. European Journal of Pharmacology. 347:1998;153-158.
48. Rudolphi K.A., Schubert P., Parkinson F.E., Fredholm B.B. Adenosine and brain ischemia. Cerebrovascular and Brain Metabolism Reviews. 4:1992;346-369.
49. 2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. Journal of Neurochemistry. 57:1991;1062-1067.
50. Schmidt C.J., Ritter J.K., Sonsalla P.K., Hanson G.R., Gibb J.W. Role of dopamine in the neurotoxic effects of methamphetamine. Journal of Pharmacology and Experimental Therapeutics. 233:1985;539-544.
51. 2 receptor-mediated excitatory actions on the nervous system. Progress in Neurobiology. 48:1996;167-189.
52. 1 receptor mediation. Neuropharmacology. 28:1989;21-25.
53. Zhang G., Franklin P.H., Murray T.F. Manipulation of endogenous adenosine in the rat prepiriform cortex modulates seizure susceptibility. Journal of Pharmacology and Experimental Therapeutics. 264:1993;1415-1424.